| Byetta (exenatide) / AstraZeneca |
2007-001221-10: Postconditioning used for the limitation of infarct size in patients with ST-elevation myocardial infarction (POSTCON). |
|
|
| Ongoing | 4 | 200 | Europe | Solution for injection, byetta | Rigshospitalet, University of Copenhagen | Patients with ST-segment elevation myocardial infarction (STEMI) are routinely treated with primary PCI (pPCI) as a world wide standard. Glucagon like peptide (GLP1) is a genuine hormone created in the gut and with well characterized receptors in heart muscle. Previous studies have proven it to be safe in human and intravenous administration for 72 hours have shown it to reduce infarct size in pPCI. | | | | |
ChiCTR-TNC-10000874: Effects of Exendin-4(GLP-1 receptor activator) on pancreatic B cell function and serum inflammatin factor in fat type 2 diabetes mellitus. |
|
|
| Completed | 4 | 10 | | Exendin-4 GLP-1 receptor activator | Shengjing Hospital of China Medical University; Level of the institution：, Shengjing Hospital of China Medical University | diabetes mellitus | | | | |
ChiCTR-TRC-10000879: Comparison of glycaemic control and beta-cell function among newly diagnosed type 2 diabetic patients treated with exenatide, insulin or rosiglitazone: a multicentre randomized parallel-group trial |
|
|
| Completed | 4 | 414 | | Exenatide injection (Byetta) ;Premixed insulin analog (Humalog Mix 25) ;Pioglitazone (Ruitong) | The Third Affiliated Hospital of Sun Yat-Sen University; Peking University People's Hospital, Eli Lilly, 5010 Program of Sun Yat-Sen University, Ministry of Health | Type 2 diabetes | | | | |
ChiCTR-IPC-15006339: Observation of the effect and safety of exenatide on hepatic biomarkers in elderly patients with type 2 diabetes complicated nonalcoholic fatty liver disease |
|
|
| Not yet recruiting | 4 | 100 | | Exenatide was initiated at 5 mcg twice daily while stopping their pre-study oral hypoglycemic drugs or taking them at reduced dose, titrated to 10 mcg twice daily after one month ;Glargine was started with 0.1IU/kg once-daily at bedtime while continuing their pre-study oral hypoglycemic drugs, and titrated with glucose levels | Metabolic Disease Hospital of Tianjin Medical University; Metabolic Disease Hospital of Tianjin Medical University, The patients will pay for the costs of the drugs and tests demanded by this clinical trial. | type 2 diabetes complicated nonalcoholic fatty liver disease | | | | |
2008-008367-95: Effect of exenatid on microcirculation in patients with type 2 diabetes mellitus and coronary artery disease |
|
|
| Ongoing | 4 | 60 | Europe | Byetta, Byetta, Byetta, Byetta | Karolinska Institutet, Inst för kliniska vetenskaper, Danderyds sjukhus | Patients with type 2 diabetes and coronary artery disease. | | | | |
2009-011158-17: Additional treatment to primary PCI: effects of ischemic postconditioning and Exenatide. |
|
|
| Ongoing | 4 | 280 | Europe | exenatide, Byetta, Byetta | Erasmus MC | Patients with a large myocardial infarction | | | | |
2008-008141-37: Effects of Exenatide on excess daytime sleepiness (EDS), wakefulness and driving performance in obese type-2 diabetes patients without sleep apnea – proof of concept study |
|
|
| Ongoing | 4 | 10 | Europe | exenatide, Byetta, Byetta | Sherwood Forest Hospitals Foundation Trust | sleepiness and lethargy among obese patients with diabetes | | | | |
| Ongoing | 4 | 20 | Europe | Victoza, Byetta, Victoza, Byetta, Victoza, Byetta | CUB - Hôpital Erasme, Friedreich's Ataxia Research Alliance | Friedreich\'s Ataxia | | | | |
ChiCTR-IPR-15006298: Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients: the second year extended follow-up study |
|
|
| Recruiting | 4 | 118 | | exenatide group ;Diet+movement | The first afilliated hospital of Xiamen University; The First afilliated Hospital of Xiamen University, The first afilliated hospital of Xiamen university | diabetes | | | | |
ChiCTR-OPC-16008152: Effect of glucagon like peptide -1 analogues of obese type 2 diabetic patients with abdominal fat |
|
|
| Completed | 4 | 36 | | Byetta treatment ;Acarbose treatment | Changzhou 2nd Peoples' Hospital Affiliated to Nanjing Medical University; Changzhou 2nd Peoples' Hospital Affiliated to Nanjing Medical University, Provincial innovation team discipline construction project | Obesity, diabetes | | | | |
ChiCTR-IPR-15006008: Effect of Exenatide on Carotid Intima-media Thickness and the Biomarkers of Atherosclerosis Compared with Insulin in Patients with Type 2 Diabetes |
|
|
| Not yet recruiting | 4 | 66 | | Exenatide ;insulin | Beijing Hospital, Ministry of Health; Beijing Hospital, Ministry of Health, AstraZeneca Investment (China) Co., Ltd | Type 2 diabetes | | | | |
ChiCTR-IPR-15005975: Intensive Lifestyle Interference for Targeted Body Weight Couple with Different Pharmacal Program in Type 2 Diabetic Patients |
|
|
| Recruiting | 4 | 147 | | Exenatide ;Humalog Mix 25 ;OAH | Affiliated Hospital of Nantong University; Affiliated Hospital of Nantong University, AstraZeneca, self-fund | Type 2 Diabetic mellitus | | | | |
ChiCTR-IPR-17010825: GLP-1 receptor agonists improvement of constitution in overweight and obese patients with T2DM |
|
|
| Recruiting | 4 | 152 | | Metformin or metformin + sulfonylurea ;Exenatide | Department of Endocrinology, Xinqiao Hospital of Chongqing City; Xinqiao Hospital, Clinical research project of the Second Affiliated Hospital of Third Military Medical University (yclkt-201420) | overweight and obese patients with T2DM | | | | |
ChiCTR1800015658: Effect of Exenatide on Carotid Intima-media Thickness and the Biomarkers of Atherosclerosis Compared with Insulin in Patients with Type 2 Diabetes |
|
|
| Recruiting | 4 | 66 | | Exenatide 10ugBid ;Aspart 30 insulin | Beijing Hospital; Beijing Hospital, AstraZeneca Investment (China) Co., Ltd. | Atherosclerosis | | | | |
ChiCTR-IIR-16008084: Effects of different treatment (metformin, spironolactone, GLP-1 receptor agonist. etc) on clinical and endocrine features and the levels of adipocytokine in patients with polycystic ovary syndrome. |
|
|
| Recruiting | 4 | 150 | | lifestyle counselling and exenatide | The third affiliated hospital of Guangzhou Medical University; The third affiliated hospital of Guangzhou Medical University, The National Natural Science Foundation of China | polycystic ovarian syndrome | | | | |
EEFDD, ChiCTR-IPR-14005568: Effects of exenatide on fat deposition in type 2 diabetic patients with BMI less than 25 kg/m2 but visceral obesity |
|
|
| Not yet recruiting | 4 | 98 | | Treatment of exenatide ;Humalog Mix 25 | Affiliated Hospital of Nantong University; Endocrinology Department, Affiliated Hospital of Nantong University, AstraZeneca Investment (China) Co., Ltd | type 2 diabetes | | | | |
ChiCTR1900020516: A comparative study of outcomes of pregnancy and delivery in overweight/obese patients with PCOS treated with exenatide or metformin |
|
|
| Recruiting | 4 | 160 | | lifestyle counselling and exenatide ;lifestyle counselling and metformin | The third affiliated hospital of Guangzhou Medical University; The third affiliated hospital of Guangzhou Medical University, The National Natural Science Foundation of China | polycystic ovarian syndrome | | | | |
ChiCTR2100041813: Compare the effects of Metformin and Exenatide on pregnancy rate and outcomes in overweight or obese PCOS women |
|
|
| Completed | 4 | 160 | | metformin and lifestyle intervention ;exenatide and lifestyle intervention | The Third Affiliated Hospital of Guangzhou Medical University; The Third Affiliated Hospital of Guangzhou Medical University, Endocrinology characteristics disciplines of internal medicine in the Third Affiliated Hospital of Guangzhou Medical University | Polycystic ovarian syndrome | | | | |
ChiCTR1900026430: Effect of Exenatide on paroxysmal atrial fibrillation with type 2 diabetes mellitus: a single-center, randomized, double-blind, controlled trial |
|
|
| Not yet recruiting | 4 | 60 | | Amiodarone first, then Exenatide; Amiodarone first, then Placebo (normal saline) | Jiangsu Province Hospital on Integration of Chinese and Western Medicine; Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Spontaneous | paroxysmal atrial fibrillation with type 2 diabetes mellitus | | | | |
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 600 | | DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin) | Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project | Type 2 diabetes | | | | |
COCONUT, NCT04307797: Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes |
|
|
| Completed | 4 | 10 | Europe | 0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min, Byetta, Glucagon 12.5ng/kg/min and 0.9% saline, Glucagon 12.5ng/kg/min | Cambridge University Hospitals NHS Foundation Trust, Antaros Medical | Type 2 Diabetes, Obesity | 10/22 | 10/22 | | |
NCT04897802: Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) |
|
|
| Recruiting | 4 | 52 | Europe | Experimental: GLP1-RA (exenatide) administration, exenatide administration, Control: Placebo administration, placebo administration (sodium chloride) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Instituto de Salud Carlos III | Hypopituitarism, Central Diabetes Insipidus, Panhypopituitarism, Psychological Disorder, Social Isolation, Hypothalamic Diseases, Pituitary Diseases, Oxytocin Deficiency | 04/24 | 12/24 | | |
NCT01107717: Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM |
|
|
| Completed | 4 | 318 | US | metformin\pioglitazone\exenatide, metformin, glyburide and glargine | The University of Texas Health Science Center at San Antonio, American Diabetes Association, Amylin Pharmaceuticals, LLC., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes | 02/23 | 02/23 | | |
|
NCT05482789: Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes |
|
|
| Recruiting | 4 | 13 | US | Exenatide | Maisa N. Feghali, MD | Gestational Diabetes | 12/24 | 12/24 | | |
